According to a report by Hasan and colleagues, NSCLC patients with higher levels of anti-BP180 IgG exhibited improved treatment response and overall survival, as well as an increased risk of cutaneous irAEs when undergoing anti-PD1/PD-L1 therapy 39. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.